Hottest Stocks (Over $10)	Hottest Stocks ($2-$10)	Biggest Losers (Over $10)	Biggest Losers ($2-$10)	Hottest Industries	Hottest Sectors	EPS / Sales Surprises
Enter Ticker Symbol:   Ticker Lookup Company Quote Company Profile Research Summary EPS Consensus Perspective Insider Transactions Price Performance

Enter any portion of the company’s name to find its corresponding ticker symbol:

Search for :

Zacks Company Profile for Portage Biotech Inc. (PRTG : NSDQ)

• Company Description    Portage Biotech Inc. is a clinical stage immuno-oncology company focused on overcoming immune resistance. The company source, nurture and develop therapies for a variety of cancers. Its drug development pipeline portfolio encompasses products or technologies with established scientific rationales, including intratumorals, nanoparticles, liposomes, aptamers, cell penetrating peptides, and virus-like particles. Portage Biotech Inc. is based in Tortola, British Virgin Islands. Number of Employees: 7

• Price / Volume Information    Yesterday's Closing Price: $5.93 Daily Weekly Monthly 20 Day Moving Average: 230,772 shares Shares Outstanding: 1.05 (millions) Market Capitalization: $6.22 (millions) Beta: 0.23 52 Week High: $13.20 52 Week Low: $2.10 Short Interest Ratio:   % Price Change % Price Change Relative to S&P 500 4 Week 7.04% 1.66% 12 Week -36.03% -44.28% Year To Date 14.70% 7.13%

• Address & Contact Information Street Address Phone / Fax Email Address Web URL CLARENCE THOMAS BUILDING P.O. BOX 4649 ROAD TOWN - TORTOLA,D8 VG1110 - ph: 203-221-7378 fax: - cpadala@lifesciadvisors.com http://www.portagebiotech.com

• General Corporate Information    Officers Ian Walters - Chairman and and Chief Executive Officer Allan Shaw - Chief Financial Officer Justin Fairchild - Vice President of Development Gregory Bailey - Director Steven Mintz - Director Peer Information - (-) - (-) - (-) - (-) - (-) - (-) Industry / Sector / Ticker Info Analyst Coverage: No Industry Group: MED-BIOMED/GENE Sector: Medical CUSIP: G7185A136 SIC: 2834 Fiscal Year Fiscal Year End: March Last Reported Quarter: 09/01/24 Next Expected EPS Date: 08/26/25 Share - Related Items Shares Outstanding: 1.05 Most Recent Split Date: 8.00 (0.05:1) Beta: 0.23 Market Capitalization: $6.22 (millions)

• EPS Information     • Dividend Information Analyst Coverage: No Dividend Yield: 0.00% Current Fiscal Quarter EPS Consensus Estimate: $ Indicated Annual Dividend: $0.00 Current Fiscal Year EPS Consensus Estimate: $ Payout Ratio: Number of Estimates in the Fiscal Year Consensus: Change In Payout Ratio: Estmated Long-Term EPS Growth Rate: % Last Dividend Paid: NA - $0.00 Next EPS Report Date: 08/26/25

• Fundamental Ratios P/E Current FY Estimate: - Trailing 12 Months: - PEG Ratio: - Price Ratios Price/Book: 8.95 Price/Cash Flow: 0.73 Price / Sales: - EPS Growth vs. Year Ago Period: 78.28% vs. Previous Quarter: 20.25% Sales Growth vs. Year Ago Period: -% vs. Previous Quarter: -% ROE 06/30/25 - - 03/31/25 - - 12/31/24 - - ROA 06/30/25 - - 03/31/25 - - 12/31/24 - - Current Ratio 06/30/25 - - 03/31/25 - - 12/31/24 - - Quick Ratio 06/30/25 - - 03/31/25 - - 12/31/24 - - Operating Margin 06/30/25 - - 03/31/25 - - 12/31/24 - - Net Margin 06/30/25 - - 03/31/25 - - 12/31/24 - - Pre-Tax Margin 06/30/25 - - 03/31/25 - - 12/31/24 - - Book Value 06/30/25 - - 03/31/25 - - 12/31/24 - - Inventory Turnover 06/30/25 - - 03/31/25 - - 12/31/24 - - Debt-to-Equity 06/30/25 - - 03/31/25 - - 12/31/24 - - Debt-to-Capital 06/30/25 - - 03/31/25 - - 12/31/24 - -

Powered by Zacks Investment Research ©